We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech company developing innovative cancer immunotherapies.